In late June, the US Food and Drug Administration could approve the Epidiolex, a pharmaceuticalized form of CBD for several severe pediatric seizure disorders. According to data recently published in the New England Journal of Medicine, the drug can reduce seizures by more than 40%. If Epidiolex wins approval it would be the first time the agency approves a drug derived from the marijuana plant. (The FDA has approved synthetic THC to treat chemotherapy-related nausea.)
While parents treating their children with CBD had to proceed based on trial and error, like a folk medicine, they also had to wonder whether dispensary purchased CBD was professionally manufactured and contained what the package said it did. GW brought a scientific understanding and pharmaceutical grade manufacturing to this promising compound.
Despite the government ruling, CBD is widely available over the counter in dispensaries in states where marijuana is legal.
At age five, Charlotte suffered 300 grand mal seizures a week, and was constantly on the brink of a medical emergency. Through online research, Charlotte’s desperate parents heard of treating Dravet with CBD. It was controversial to pursue medical marijuana for such a young patient, but when they gave Charlotte oil extracted from high-CBD cannabis, her seizures stopped almost completely. In honor of her progress, high-CBD cannabis is sometimes known as Charlotte’s Web.
In early May, a federal court declined to protect cannabidiol (CBD), a chemical produced by the cannabis plant, from federal law enforcement, despite widespread belief in its medical value.
The ruling was contrary to existing evidence, which suggests the chemical is safe and could have multiple important uses as medicine. Many cannabis advocates consider it a miracle medicine, capable of relieving conditions as disparate as depression, arthritis and diabetes.
CBD first came to public attention in a 2013 CNN documentary called Weed. The piece, reported by Dr Sanjay Gupta, featured a little girl in Colorado named Charlotte, who had a rare life-threatening form of epilepsy called Dravet syndrome.
I’m ordinarily not a chocolate or sweets person. But when it comes to edibles, this delivery method works best for me when I’m traveling and away from my kitchen. Kiva’s products are what I carry whenever work (or pleasure) takes me on extended trips. The ginger dark chocolate and espresso dark chocolate are my favorites. They’ve got just enough THC and CBD to help ward off jet lag and fatigue. I also take them when I’m extra sore from running or Krav Maga. (It really does wonders for pain and inflammation.) But it’d be a disservice if I only mentioned Kiva’s chocolates. The company also offers Camino gummies, of which the sparkling pear and wild berry, are superb. The THC-only Terra Bites chocolate-covered blueberries are a gift from the gods—they work, they fit nicely in my purse, and they’re delicious. Also: a single dose (5mg) is low enough so that when paired with a CBD-only confection, such as Lord Jones’ gumdrops, there’s not really a high. You only get a pleasant mellowness that radiates throughout your body, which is almost akin to a mild boozy buzz—in a happy and good way. (In budtender lingo, it’s called a body high.)
Trying a THC-CBD edible for the very first time? These goji berries are the way to go.
Cheeba Chews has a major fan base partially because of its potency and consistent dosage. And for . [+] good reason. Each miniscule 1:1 chew contains 50mg of THC and 50mg of CBD. So consume it with caution.
Aurora Elixirs is marketed as a mixer for cocktail creation. It is, however, a very good drink that . [+] can stand alone.
I used to pop Aleve as if they were Tic Tacs. Three at a time, four at a time—whatever would get the job done. And if that meant taking 15 gel caps a day so be it. Liver be damned.
Mighty Health’s Balance formula is exactly what you need if you don’t care for chocolate, tinctures, olive oil, gummies, or vapes. Balance comes in capsule form. And while it contains a good dose of CBD, it’s not just a CBD pill. It’s a neutraceutical, which is technically not recognized as a separate category by the F.D.A—instead, neutraceuticals are pretty much treated like dietary supplements. This one in particular contains ashwagandha, L-Theanine, theobromine, and curcumin. I know, it sounds very Goop-y. But the most important thing is its per-capsule CBD content, which is a good dose at 10mg.
I’m not big on CBD drinks. But I can appreciate that others are. And in the cannabis world, CBD and THC drinks abound: There’s CBD Living Water, Recess, Vybes, Lagunitas HiFi Hops, Somatik Cold Brew, Kikoko Tea, and more. But Aurora Elixirs is what I was drawn to. It’s marketed as a mixer for when you want to make cocktails. I, however, think it’s perfectly fine on its own. Pop it in the fridge to cool and drink it whenever you need it. No complicated recipe or garnish required.
Recent legislative change has allowed increased access to cannabis products in many jurisdictions. In some locations, this includes over-the-counter (OTC) and/or online access to products containing cannabidiol (CBD), a non-intoxicating cannabinoid with therapeutic properties. Here we compared the availability of CBD products and the associated legislative and regulatory background in nine selected countries.
Accessibility of CBD products was examined in the USA, Canada, Germany, Ireland, United Kingdom, Switzerland, Japan, Australia, and New Zealand as of May 2020. Regulatory and other relevant documents were obtained from government agency websites and related sources. Relevant commercial websites and some physical retailers were visited to verify access to CBD-containing products and the nature of the products available.
A range of CBD products appeared to be accessible without prescription in seven out of nine countries reviewed. Australia and New Zealand were the exceptions where clinician prescription was required to access any CBD-containing product. CBD products commonly available without prescription included oils, gel capsules, purified crystal and topical products. The daily recommended doses with orally administered non-prescription products were typically well below 150 mg and substantially lower than the doses reported to have therapeutic effects in published clinical trials (e.g., 300-1500 mg). The legal foundations enabling access in several countries were often unclear, with marketed products sometimes failing to meet legal requirements for sale. There was an obvious disparity between federal directives and available products in both the USA and European countries examined.
There are a variety of approaches in how countries manage access to CBD products. Many countries appear to permit OTC and online availability of CBD products but often without legislative clarity. As consumer demand for CBD escalates, improved legislation, guidelines and quality control of CBD products would seem prudent together with clinical trials exploring the therapeutic benefits of lower-dose CBD formulations.